SCHEMBL10165567

SCHEMBL10165567

Cc1cccc2c1ccn2C(C)(C)C(=O)C(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 2/20 0.44
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
SLC9A1 P19634 1/20 0.35
NR3C2 P08235 1/20 0.34
NOTUM Q6P988 2/20 0.34
KDM4E B2RXH2 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2A6 P11509 1/20 0.33
TP53 P04637 1/20 0.33
ALDH1A1 P00352 2/20 0.33
F10 P00742 1/20 0.32
PRMT5 O14744 1/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
PTPN1 P18031 1/20 0.32
KMT2A Q03164 3/20 0.32
MEN1 O00255 2/20 0.32
MAPT P10636 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13209712 0.79 HTR2A (0.45) FABP4HTR2AHTR2CKDM4ECYP1A2
SCHEMBL10165552 0.73 HTR2A (0.51) FABP4HTR2AHTR2CKDM4EALDH1A1
SCHEMBL10165539 0.71 HTR2A (0.42) FABP4HTR2AHTR2CSLC9A1NR3C2
SCHEMBL11573644 0.69 NOTUM (0.67) FABP4HTR2AHTR2CSLC9A1NOTUM
SCHEMBL5623104 0.69 NOTUM (0.49) FABP4HTR2AHTR2CSLC9A1NOTUM
SCHEMBL424580 0.69 L3MBTL1 (0.48) FABP4HTR2AHTR2CNOTUMKMT2A
SCHEMBL9429365 0.68 FABP4 (0.56) FABP4NOTUMKDM4EALDH1A1KMT2A
SCHEMBL31560801 0.68 NOTUM (0.55) NR3C2NOTUMKDM4ECYP1A2ALDH1A1
SCHEMBL28025537 0.67 HTR2A (0.47) FABP4HTR2AHTR2CSLC9A1NOTUM
SCHEMBL4705986 0.67 FABP4 (0.40) FABP4HTR2AHTR2CSLC9A1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883766-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-11-11 US disclosed
US-20120208790-A1 ION CHANNEL MODULATORS AND METHODS OF USE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-16 US disclosed
US-8193194-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208790-A1 ION CHANNEL MODULATORS AND METHODS OF USE CACNA1G, CACNA1C, CACNA1B FABP4 4090/4885HTR2A 720/4885HTR2C 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.